製品番号: HY-B0523

Anagrelide

3 Cited Publications

カスタマーレビュー

Based on 3 publication(s) in Google Scholar

Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.87%
CAS 番号: 68475-42-3
分子式: C₁₀H₇Cl₂N₃O
分子量:256.09

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Anagrelide 構造式

CAS 番号: 68475-42-3

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (3)
溶剤 & 溶解度
- 体外
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

PDEIII^[1]

Phosphodiesterase (PDE) アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	EC₅₀	4 nM Compound: 1	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth Antiproliferative activity against human HeLa cells assessed as reduction in cell growth	[PMID: 37077378]
HeLa	EC₅₀	5.12 nM Compound: 1	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	[PMID: 37077378]
HeLa	EC₅₀	6.67 nM Compound: 1	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 37077378]
Platelet	EC₅₀	<1 μg/mL Compound: 1	Antiplatelet aggregation activity in rabbit platelet-rich plasma assessed as reduction in ADP-induced aggregation incubated for 5 mins by aggregometry Antiplatelet aggregation activity in rabbit platelet-rich plasma assessed as reduction in ADP-induced aggregation incubated for 5 mins by aggregometry	[PMID: 37077378]
Platelet	EC₅₀	0.08 μM Compound: 1	Antiplatelet aggregation activity in human rich plasma assessed as reduction in collagen-induced platelet aggregation Antiplatelet aggregation activity in human rich plasma assessed as reduction in collagen-induced platelet aggregation	[PMID: 37077378]
Platelet	EC₅₀	0.08 μM Compound: 1	Antiplatelet aggregation activity in rhesus monkey platelet rich plasma assessed as reduction in collagen-induced platelet aggregation Antiplatelet aggregation activity in rhesus monkey platelet rich plasma assessed as reduction in collagen-induced platelet aggregation	[PMID: 37077378]
Platelet	EC₅₀	0.15 μM Compound: 1	Antiplatelet aggregation activity in Sprague-Dawley rat platelet rich plasma assessed as reduction in collagen-induced platelet aggregation Antiplatelet aggregation activity in Sprague-Dawley rat platelet rich plasma assessed as reduction in collagen-induced platelet aggregation	[PMID: 37077378]
Platelet	EC₅₀	0.27 μM Compound: 1	Antiplatelet aggregation activity in Sprague-Dawley rat platelet rich plasma assessed as reduction in ADP-induced platelet aggregation Antiplatelet aggregation activity in Sprague-Dawley rat platelet rich plasma assessed as reduction in ADP-induced platelet aggregation	[PMID: 37077378]
Platelet	EC₅₀	0.31 μM Compound: 1	Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation	[PMID: 37077378]
Platelet	EC₅₀	0.31 μM Compound: 1	Antiplatelet aggregation activity in dog rich plasma assessed as reduction in ADP-induced platelet aggregation Antiplatelet aggregation activity in dog rich plasma assessed as reduction in ADP-induced platelet aggregation	[PMID: 37077378]
Platelet	EC₅₀	0.39 μM Compound: 1	Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation	[PMID: 37077378]
Platelet	EC₅₀	0.4 μM Compound: 1	Antiplatelet aggregation activity in human rich plasma assessed as reduction in ADP-induced platelet aggregation Antiplatelet aggregation activity in human rich plasma assessed as reduction in ADP-induced platelet aggregation	[PMID: 37077378]
Platelet	EC₅₀	0.5 μM Compound: 1	Antiplatelet aggregation activity in rhesus monkey platelet rich plasma assessed as reduction in ADP-induced platelet aggregation Antiplatelet aggregation activity in rhesus monkey platelet rich plasma assessed as reduction in ADP-induced platelet aggregation	[PMID: 37077378]
Platelet	EC₅₀	0.7 μM Compound: 1	Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of thrombin-induced platelet aggregation	[PMID: 37077378]
Platelet	EC₅₀	0.74 μM Compound: 1	Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of antigen-antibody-induced platelet aggregation Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of antigen-antibody-induced platelet aggregation	[PMID: 37077378]
Platelet	EC₅₀	1.2 μM Compound: 1	Antiplatelet aggregation activity in rabbit platelet rich plasma assessed as reduction in ADP-induced platelet aggregation Antiplatelet aggregation activity in rabbit platelet rich plasma assessed as reduction in ADP-induced platelet aggregation	[PMID: 37077378]
Platelet	EC₅₀	27 nM Compound: 1	Antiplatelet activity against ADP-induced Wistar rat platelet aggregation assessed as inhibition of platelet aggregation Antiplatelet activity against ADP-induced Wistar rat platelet aggregation assessed as inhibition of platelet aggregation	[PMID: 37077378]

体外実験

Anagrelide potently inhibits the development of marrow megakaryocytes (IC₅₀=26 nM)^[1].
Anagrelide (0.05, 0.3, 1 µM; 12-day) inhibits only megakaryocytic cell growth not non-megakaryocytic cells^[2].
Anagrelide (0.1-10000 nM) induces a cytotoxic effect in the GIST882 cell line^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

Megakaryocytic and non-megakaryocytic cells
Concentration:

0.05, 0.3, 1 µM
Incubation Time:

12-day
Result:

Inhibited only megakaryocytic cell growth at every concentration tested

Cell Cytotoxicity Assay^[3]

Cell Line:

GIST882 and GIST48 cell line
Concentration:

0.1, 1, 10, 100, 1000, 10000 nM
Incubation Time:
Result:

Induced a cytotoxic effect in the GIST882 cell line (IC₅₀= 16 nM), but was only weakly active in the GIST48 cell line.

体内実験

Anagrelide (5 mg/kg/bid; for 10 days) inhibits or reduces tumor growth in GIST2B, GIST9, GIST882 model models^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Adult female athymic mice bearing GIST2B, GIST3, GIST9, GIST882 model^[3]
Dosage:

5 mg/kg
Administration:

Twice daily; for 10 days
Result:

Inhibited or reduced tumor growth in three (GIST2B, GIST9, GIST882) of these four models.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 68475-42-3
性状 Solid
分子量 256.09
分子式 C₁₀H₇Cl₂N₃O
Color White to off-white
SMILES

O=C1NC2=NC3=C(C(Cl)=C(Cl)C=C3)CN2C1
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (3)

All

Sort by:

Journal Impact Factor

Cell Metab

Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry. [Abstract]

2022 Mar 1;34(3):424-440.e7. PMID: 35150639
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
Exp Hematol

Purging myeloma cell contaminants and simultaneous expansion of peripheral blood mobilised stem cells. [Abstract]

2024 Mar:131:104138. PMID: 38151170

溶剤 & 溶解度

体外:

DMSO : 2.56 mg/mL (10.00 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.9049 mL

19.5244 mL

39.0488 mL

5 mM

0.7810 mL

3.9049 mL

7.8098 mL

10 mM

0.3905 mL

1.9524 mL

3.9049 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (275 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Guosu Wang, et al. Comparison of the biological activities of Anagrelide and its major metabolites in haematopoietic cell cultures. Br J Pharmacol. 2005 Oct;146(3):324-32. [Content Brief]

[2]. Y Hong, et al. Comparison between Anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of Anagrelide for the megakaryocytic lineage. Leukemia. 2006 Jun;20(6):1117-22. [Content Brief]

[3]. Olli-Pekka Pulkka, et al. Anagrelide for Gastrointestinal Stromal Tumor. Clin Cancer Res. 2019 Mar 1;25(5):1676-1687. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.9049 mL	19.5244 mL	39.0488 mL	97.6219 mL
DMSO	5 mM	0.7810 mL	3.9049 mL	7.8098 mL	19.5244 mL

Keywords

Anagrelide

3 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Anagrelide

Apoptosis Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Coagulation and Anti-coagulation Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Drug Fragment Library

MedChemExpress（MCE）の使用を引用している文献 Anagrelide

Phosphodiesterase (PDE) アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (3)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Anagrelide 関連分類

HY-B0523 関連分類